Perspective Therapeutics, Inc. $CATX Shares Acquired by Avidity Partners Management LP

Avidity Partners Management LP grew its stake in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 7.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,210,733 shares of the company’s stock after buying an additional 216,700 shares during the period. Perspective Therapeutics accounts for 2.5% of Avidity Partners Management LP’s investment portfolio, making the stock its 8th largest holding. Avidity Partners Management LP owned about 4.32% of Perspective Therapeutics worth $8,830,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of CATX. Geode Capital Management LLC boosted its holdings in shares of Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after buying an additional 188,887 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Perspective Therapeutics by 118.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after buying an additional 405,612 shares in the last quarter. Walleye Capital LLC boosted its holdings in shares of Perspective Therapeutics by 375.8% in the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after buying an additional 148,013 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of Perspective Therapeutics by 44.4% in the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after buying an additional 60,019 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Perspective Therapeutics by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after buying an additional 25,697 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on CATX shares. UBS Group upped their price target on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. B. Riley Financial upped their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. HC Wainwright upped their price target on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Finally, BTIG Research reiterated a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Trading Down 0.7%

CATX stock opened at $2.95 on Friday. The company has a fifty day moving average price of $3.93 and a 200 day moving average price of $3.77. Perspective Therapeutics, Inc. has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. Analysts forecast that Perspective Therapeutics, Inc. will post -1.13 EPS for the current fiscal year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.